Walder Wyss advised CorFlow Therapeutics AG on the deal. Kellerhals Carrard advised Broadview Ventures and Panakes Partners. CorFlow Therapeutics AG completed a series B financing round...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised CRISPR Therapeutics on the issuance. CRISPR Therapeutics AG (NASDAQ: CRSP), a Switzerland-based biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised ANYbotics AG on CHF 45m Series B Round. ANYbotics, a leading maker of four-legged robots, closed its CHF 45 million series B financing round....
You must be a Standard 1 Year member to access this content.
Walder Wyss has advised the selling founders on the deal. Vischer advised the buyer. Nautilus, Inc. (NYSE: NLS), an innovation leader in home fitness, has acquired...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised lead investor Revaia on the deal. Wenger Vieli advised Frontify. Frontify AG, a leading provider of brand management software, raised an additional USD...
You must be a Standard 1 Year member to access this content.
Walder Wyss has advised Imburse on this transaction. Cloud based payments integration platform provider Imburse has announced the completion of a USD 12 million Series A...
You must be a Standard 1 Year member to access this content.
